• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific blows Wall Street away, even as CRM sales lose 10%

Boston Scientific blows Wall Street away, even as CRM sales lose 10%

April 19, 2012 By MassDevice staff

Boston Scientific logo

Boston Scientific’s (NYSE:BSX) stock jumped in morning trading today as the company nearly doubled Wall Street’s expectations for its 1st quarter earnings amid dwindling cardiac rhythm management sales.

The Natick, Mass.-based med-tech titan posted profits of $113 million, or 8¢ per diluted share, which is more than twice the $46 million, or 3¢ per share, earned during the same period last year. Excluding 1-time charges, the company posted earnings of 15¢ per share, nearly doubling analysts’ 8¢ forecasts for the quarter.

The news generated a flurry of activity on The Street, where BSX shares were up 7% to $5.93 as of about 10 a.m. today.

The company’s bottom line swelled but overall sales decreased, especially in CRM and inverventional cardiology.

Boston Scientific reported revenues of $1.87 billion during the 3 months ended March 31, a 3% decline from the $1.93 billion posted for the same period last year.

Particularly hard hit was the device maker’s CRM division, where sales were down 10% to $501 million. Interventional cardiology lost 5%, coming to $603 million for the quarter.

The decline was partially offset by 5% growth in Boston Scientific’s endoscopy business, 8% growth in peripheral interventions and 8% growth in neuromodulation, according to the latest earnings report.

Boston Scientific isn’t the only device giant facing dwindling CRM sales. In a Q1 earnings report, released yesterday, St. Jude Medical (NYSE:STJ) posted a 4% decrease in worldwide CRM, a 3% decrease in ICDs and a 4% decline in pacemakers.

Both companies are expected to figure large in next month’s annual meeting of the Heart Rhythm Society, but for very different reasons.

The foofaraw over St. Jude’s recalled Riata defibrillator leads is slated for top billing, according to a pair of Leerink Swann analysts citing the views of a "prominent high-volume electrophysiologist."

"The physician noted that doctors at his hospital – a high-volume quaternary referral center – had already cut back on their STJ device usage, in an effort to be extra cautious and stay away from any potential device performance controversies. This specific physician’s concern appears to be with ‘inside-out abrasion’ and ‘short circuiting,’ which he suggested could occur with the older generation STJ leads but not with competitors’ products," wrote Leerink analysts Rick Wise and Miroslava Minkova in a note to investors. "This physician seemed to also have an overall positive view on BSX’s new Incepta, Punctua, and Energen devices. He emphasized he felt BSX had ‘excellent ICD leads’ – positioning BSX well amid the current lead-related controversies."

Boston Scientific could also benefit from the leadless ICD technology it agreed to acquire last month along with Cameron Health in a deal worth up to $1.35 billion. The S-ICD device is slated for a review by the FDA’s circulatory devices panel April 26.

The company predicted full-year sales of between $7.35-$7.65 billion, with earnings in the range of 25¢-38¢ per share and adjusted earnings of 60¢-70¢. For Q2, the company expects revenues in the range of $1.85-$1.95 billion, with earnings between 6¢-9¢ per share and adjusted earnings of 14¢-17¢.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Boston Scientific, Cardiac Rhythm Management, Q1

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy